Filing Flows › Kopin (KOPN) › Q2 2026 › vs Q2 2025
Kopin (KOPN) Q2 2026 vs Q2 2025 (year over year)
Kopin's revenue rose $4.3M (+51%) from $8.5M in Q2 2025 to $12.7M in Q2 2026. The biggest changes: License and Other Revenues +$7K (+15%).
Kopin, Q2 2026: revenue $12.7M (+51% year over year), operating margin -27.5%, net earnings $831K, operating cash flow −$4.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Research and Development Revenues | $2.2M | $908K | $1.3M | +139% |
| R&D | $2.2M | $908K | $1.3M | +139% |
| Medical | $309K | $213K | $96K | +45% |
| License and Other Revenues | $56K | $49K | $7K | +15% |
| Revenue | $12.7M | $8.5M | $4.3M | +51% |
| Other income, net | $2.2M | $347K | $1.9M | +547% |
| Income tax benefit | $2.1M | −$52K | $2.1M | — |
| Costs & expenses | $17.1M | $14.0M | $3.1M | +22% |
| Operating costs | $16.2M | $13.9M | $2.3M | +17% |
| Net earnings | $831K | −$5.2M | $6.0M | — |
| Research & development | $1.2M | $1.5M | −$284K | -19% |
| SG&A | $5.1M | $4.9M | $227K | +5% |
| Other operating costs | $9.9M | $7.5M | $2.4M | +32% |
| Operating cash sources | $6.3M | −$35K | $6.4M | — |
| Depreciation & amortization | $184K | $225K | −$41K | -18% |
| Share-based compensation | $974K | $748K | $226K | +30% |
| Cash used in operations | $4.3M | $4.2M | $173K | +4% |
| Working capital & other | $6.3M | −$35K | $6.4M | — |
Questions
How much did Kopin's revenue grow year over year in Q2 2026?
Kopin's revenue rose $4.3M (+51%) from $8.5M in Q2 2025 to $12.7M in Q2 2026.
What drove Kopin's revenue change in Q2 2026?
License and Other Revenues +$7K (+15%).